PMS-SALBUTAMOL SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SALBUTAMOL (SALBUTAMOL SULFATE)

Disponibbli minn:

PHARMASCIENCE INC

Kodiċi ATC:

R03AC02

INN (Isem Internazzjonali):

SALBUTAMOL

Dożaġġ:

2MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

SALBUTAMOL (SALBUTAMOL SULFATE) 2MG

Rotta amministrattiva:

INHALATION

Unitajiet fil-pakkett:

2.5ML

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0108887001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2010-05-04

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL
Salbutamol Sulphate Inhalation Solution, BP
0.05%; 0.1%; 0.2%
0.5 mg/mL; 1 mg/mL; 2 mg/mL
BRONCHODILATOR
Beta
2
-adrenergic stimulant
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
August 10, 2018
www.pharmascience.com
Submission Control No: 217525
_ _
_pms-SALBUTAMOL Product Monograph Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
8
DOSAGE AND ADMINISTRATION
................................................................................
9
OVERDOSAGE
................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND STABILITY
.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
...............................................................................
14
PHARMACEUTICAL INFORMATION
.........................................................................
14
CLINICAL TRIALS
...........................................................................................